{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:38:15Z","timestamp":1790678295442,"version":"4.1.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA142840"],"award-info":[{"award-number":["R01CA142840"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010249","name":"Indiana University School of Medicine","doi-asserted-by":"crossref","award":["start-up award"],"award-info":[{"award-number":["start-up award"]}],"id":[{"id":"10.13039\/100010249","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non\u2013small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during, and after RT administration and then correlated to overall survival (OS), progression-free survival, and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months of median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival.<\/jats:p>\n                  <jats:p>Significance: Radiotherapy appears to influence systemic IDO activity and to exert a significant impact on metastatic risk and overall survival, with possible implications for defining a biomarker to optimize radiation dose in patients to improve outcomes. Cancer Res; 78(3); 809\u201316. \u00a92017 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-17-2995","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T17:20:37Z","timestamp":1510161637000},"page":"809-816","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients"],"prefix":"10.1158","volume":"78","author":[{"given":"Weili","family":"Wang","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[{"name":"2Institute of Cellular Medicine, Faculty of Medical Sciences, Framlington Place, Newcastle University, Newcastle-upon-Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yue","family":"Jin","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jolly","sequence":"additional","affiliation":[{"name":"3Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zang","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanmei","family":"Wu","sequence":"additional","affiliation":[{"name":"5Indiana University School of Informatics and Computing, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhu","family":"Pi","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mellor","sequence":"additional","affiliation":[{"name":"2Institute of Cellular Medicine, Faculty of Medical Sciences, Framlington Place, Newcastle University, Newcastle-upon-Tyne, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming (Spring)","family":"Kong","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"2022061706042980500_bib1","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA: Cancer J Clin"},{"key":"2022061706042980500_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0360-3016(00)01401-2","article-title":"Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach","volume":"49","author":"Tyldesley","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022061706042980500_bib3","first-page":"289","article-title":"Silvia Formenti on the promise of combining radiotherapy and immunotherapy to treat cancer","volume":"30","author":"Formenti","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"2022061706042980500_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706042980500_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"2022061706042980500_bib6","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res"},{"key":"2022061706042980500_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"2022061706042980500_bib8","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI31911","article-title":"Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase","volume":"117","author":"Sharma","year":"2007","journal-title":"J Clin Invest"},{"key":"2022061706042980500_bib9","doi-asserted-by":"crossref","first-page":"75407","DOI":"10.18632\/oncotarget.12249","article-title":"Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment","volume":"7","author":"Schafer","year":"2016","journal-title":"Oncotarget"},{"key":"2022061706042980500_bib10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ni.2077","article-title":"Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells","volume":"12","author":"Pallotta","year":"2011","journal-title":"Nat Immunol"},{"key":"2022061706042980500_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"2022061706042980500_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines3030703","article-title":"The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity","volume":"3","author":"Mbongue","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"2022061706042980500_bib13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0900408","article-title":"Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression","volume":"183","author":"Liu","year":"2009","journal-title":"J Immunol"},{"key":"2022061706042980500_bib14","doi-asserted-by":"crossref","first-page":"384726","DOI":"10.1155\/2011\/384726","article-title":"Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma","volume":"2011","author":"Zhang","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"2022061706042980500_bib15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061706042980500_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/GCO.0b013e3283409c79","article-title":"Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer","volume":"23","author":"Ino","year":"2011","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2022061706042980500_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5114\/pjp.2015.57249","article-title":"The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor beta and interferon gamma in metastatic lymph nodes in malignant melanoma","volume":"66","author":"Pelak","year":"2015","journal-title":"Polish J Pathol"},{"key":"2022061706042980500_bib18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3324\/haematol.13112","article-title":"High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome","volume":"93","author":"Chamuleau","year":"2008","journal-title":"Haematologica"},{"key":"2022061706042980500_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1139\/o11-077","article-title":"Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy","volume":"90","author":"Cavia-Saiz","year":"2012","journal-title":"Biochem Cell Biol"},{"key":"2022061706042980500_bib20","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1158\/1078-0432.CCR-10-2805","article-title":"Prognostic immune markers in non-small cell lung cancer","volume":"17","author":"Suzuki","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061706042980500_bib21","doi-asserted-by":"crossref","first-page":"e23428","DOI":"10.4161\/onci.23428","article-title":"Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer","volume":"2","author":"Creelan","year":"2013","journal-title":"Oncoimmunology"},{"key":"2022061706042980500_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.lungcan.2009.05.001","article-title":"Increased serum kynurenine\/tryptophan ratio correlates with disease progression in lung cancer","volume":"67","author":"Suzuki","year":"2010","journal-title":"Lung Cancer"},{"key":"2022061706042980500_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2004.12.060","article-title":"CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan","volume":"63","author":"Chapet","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022061706042980500_bib24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ijrobp.2006.01.051","article-title":"Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis","volume":"65","author":"Kong","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022061706042980500_bib25","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.4049\/jimmunol.1103668","article-title":"Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells","volume":"188","author":"Huang","year":"2012","journal-title":"J Immunol"},{"key":"2022061706042980500_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/clinchem\/48.3.579","article-title":"More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC","volume":"48","author":"Laich","year":"2002","journal-title":"Clin Chem"},{"key":"2022061706042980500_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/PPO.0b013e3181eb3343","article-title":"Indoleamine 2,3-dioxygenase: is it an immune suppressor?","volume":"16","author":"Soliman","year":"2010","journal-title":"Cancer J"},{"key":"2022061706042980500_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022061706042980500_bib29","doi-asserted-by":"crossref","first-page":"e957994","DOI":"10.4161\/21624011.2014.957994","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"3","author":"Vacchelli","year":"2014","journal-title":"Oncoimmunology"},{"key":"2022061706042980500_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2051-1426-2-21","article-title":"The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma","volume":"2","author":"Li","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2022061706042980500_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1078-0432.CCR-13-1560","article-title":"Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase","volume":"20","author":"Iversen","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/3\/809\/2774789\/809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/3\/809\/2774789\/809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:17:43Z","timestamp":1655471863000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/3\/809\/632388\/IDO-Immune-Status-after-Chemoradiation-May-Predict"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,1,31]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-17-2995","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22419806.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22419806","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6510467.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6510467","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]}}}